SEC Tracker
Get the app

Filana Therapeutics FLNA

Filana Therapeutics reports net loss of $10.73 million

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $10.73 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$0.22 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $46.99 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Filana Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Anixa Biosciences ANIX public float $85M, Apr 30, 2025, over 18 months old
  2. GENELUX GNLX public float $89M, Jun 30, 2025
  3. Entera Bio ENTX public float $85M, Jun 30, 2025
  4. Immunic IMUX public float $83M, Jun 30, 2025
  5. Coherus Oncology CHRS public float $82M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.